CA3025492A1 - Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto - Google Patents

Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto Download PDF

Info

Publication number
CA3025492A1
CA3025492A1 CA3025492A CA3025492A CA3025492A1 CA 3025492 A1 CA3025492 A1 CA 3025492A1 CA 3025492 A CA3025492 A CA 3025492A CA 3025492 A CA3025492 A CA 3025492A CA 3025492 A1 CA3025492 A1 CA 3025492A1
Authority
CA
Canada
Prior art keywords
alkyl
optionally substituted
independently selected
compound according
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3025492A
Other languages
English (en)
French (fr)
Inventor
M. Arshad Siddiqui
Stephane Ciblat
Martin DERY
Lea CONSTANTINEAU-FORGET
Chantal Grand-Maitre
Xiangyu GUO
Sanjay Srivastava
Gerald W. Shipps
Alan B. Cooper
Nicolas BRUNEAU-LATOUR
Vu Linh Ly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bantam Pharmaceutical LLC
Original Assignee
Bantam Pharmaceutical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bantam Pharmaceutical LLC filed Critical Bantam Pharmaceutical LLC
Publication of CA3025492A1 publication Critical patent/CA3025492A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3025492A 2015-06-01 2016-06-01 Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto Abandoned CA3025492A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562169376P 2015-06-01 2015-06-01
US62/169,376 2015-06-01
PCT/US2016/035288 WO2016196644A1 (en) 2015-06-01 2016-06-01 Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto

Publications (1)

Publication Number Publication Date
CA3025492A1 true CA3025492A1 (en) 2016-12-08

Family

ID=56118071

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3025492A Abandoned CA3025492A1 (en) 2015-06-01 2016-06-01 Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto

Country Status (9)

Country Link
US (2) US10537558B2 (enExample)
EP (1) EP3303332A1 (enExample)
JP (1) JP6707630B2 (enExample)
CN (1) CN108349962A (enExample)
BR (1) BR112017025851A2 (enExample)
CA (1) CA3025492A1 (enExample)
IL (1) IL255898A (enExample)
MX (1) MX2017015456A (enExample)
WO (1) WO2016196644A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6707630B2 (ja) 2015-06-01 2020-06-10 バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーBantam Pharmaceutical, Llc 置換ピラゾールおよびピロール化合物、および翻訳開始の阻害およびこれらに関連する疾患および障害の治療のためにこれらを用いる方法
AU2017366901B2 (en) * 2016-11-30 2022-09-29 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
BR112019011035A2 (pt) * 2016-11-30 2019-10-15 Bantam Pharmaceutical Llc métodos de uso de compostos pirazol e pirazol substituído e para o tratamento de doenças hiperproliferativas
JP7301042B2 (ja) 2018-03-30 2023-06-30 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除組成物
WO2019236966A2 (en) 2018-06-07 2019-12-12 Bantam Pharmaceutical, Llc Methods of treatment of cancer with substituted pyrrole and pyrazole compounds and diagnosis of cancers susceptible to treatment with substituted pyrrole and pyrazole compounds
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
CN110950848B (zh) * 2018-09-27 2024-03-26 徐诺药业 新型氨基吡唑类衍生物的合成与应用
EP3976605B1 (en) * 2019-05-31 2025-08-20 Bantam Pharmaceutical, LLC Methods for making thiazolylpyrazole carboxylic acids and intermediates therefor
WO2021085550A1 (ja) 2019-11-01 2021-05-06 ユニマテック株式会社 含フッ素ピリミジン化合物およびその製造方法
AU2021230289A1 (en) * 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
CA3229560A1 (en) 2021-08-25 2023-03-02 Christopher L. Vandeusen Eif4e inhibitors and uses thereof
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク セラピューティクス, インコーポレイテッド eIF4E阻害剤及びその使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342851A (en) * 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
IT1301968B1 (it) * 1998-07-30 2000-07-20 Zambon Spa Derivati di eritromicina ad attivita' antibiotica
ES2208227T3 (es) * 1999-12-03 2004-06-16 Pfizer Products Inc. Compuestos de heteroarilfenilpirazol como agentes antiinflamatorios/analgesicos.
EP1513534A2 (en) * 2002-04-04 2005-03-16 Cv Therapeutics, Inc. Compounds for increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis
US20060194807A1 (en) 2003-04-03 2006-08-31 Cosford Nicholas D P Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
JP2006523701A (ja) * 2003-04-18 2006-10-19 メルク エンド カムパニー インコーポレーテッド ナトリウムチャネルブロッカーとしてのビアリール置換チアゾール、オキサゾール、およびイミダゾール
WO2007138110A2 (en) 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
MX2010001462A (es) * 2007-08-27 2010-03-01 Basf Se Compuestos de pirazol para controlar plagas de invertebrados.
CN102056907B (zh) * 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
CA2722733C (en) 2008-04-28 2016-02-23 Kyorin Pharmaceutical Co., Ltd. Cyclopentylacrylamide derivative
JP5937102B2 (ja) * 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ1デルタ(ck1デルタ)阻害剤
WO2014066304A1 (en) 2012-10-22 2014-05-01 Egenix, Inc. Compositions and methods for treating or preventing diseases or disorders associated with misregulated eif4e
CA2943659C (en) 2014-03-27 2023-04-25 Merck Patent Gmbh Pyridyl piperidines
WO2016169886A1 (en) 2015-04-24 2016-10-27 Syngenta Crop Protection Ag Pesticidally active polycyclic derivatives with sulfur substituted five-membered ring heterocyles
JP6707630B2 (ja) 2015-06-01 2020-06-10 バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーBantam Pharmaceutical, Llc 置換ピラゾールおよびピロール化合物、および翻訳開始の阻害およびこれらに関連する疾患および障害の治療のためにこれらを用いる方法

Also Published As

Publication number Publication date
US10537558B2 (en) 2020-01-21
JP6707630B2 (ja) 2020-06-10
US20180311218A1 (en) 2018-11-01
JP2018521119A (ja) 2018-08-02
IL255898A (en) 2018-01-31
MX2017015456A (es) 2018-11-29
BR112017025851A2 (pt) 2018-10-16
WO2016196644A1 (en) 2016-12-08
EP3303332A1 (en) 2018-04-11
CN108349962A (zh) 2018-07-31
US20200261424A1 (en) 2020-08-20
US11602526B2 (en) 2023-03-14

Similar Documents

Publication Publication Date Title
CA3025492A1 (en) Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto
JP7775430B2 (ja) Irak4阻害剤としての二環式ヘテロシクリル誘導体
US12150934B2 (en) Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases
JP7373992B2 (ja) 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法
ES3039644T3 (en) Novel ferroportin inhibitors
CA2476343C (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
US11168079B2 (en) Alkene compounds as farnesoid x receptor modulators
WO2014160873A1 (en) Benzimidazolone derivatives as bromodomain inhibitors
HK1217482A1 (en) Enzyme modulators and therapies
WO2008068470A1 (en) Antibacterial polycyclic urea compounds
US11370785B2 (en) Multicyclic compounds as farnesoid X receptor modulators
KR102414365B1 (ko) 신규 화합물 및 그의 약리적으로 허용가능한 염
CA2962312A1 (en) 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators
AU2015242219A1 (en) Sulfonamide compounds as Voltage gated sodium channel modulators
IL322435A (en) Covalent modifiers of Akt1 and their uses
CA2810489A1 (en) Prostaglandin d synthase inhibitory piperidine compounds
CN108373476B (zh) 一种激酶抑制剂及其制备和应用
AU2016378154B2 (en) Phenylimidazole compound
CN112939966B (zh) 嘧啶衍生物、其制备及应用
CN120359220A (zh) 苯并咪唑衍生物
TW202519208A (zh) 用於治療用途的糖原合酶激酶3的抑制劑

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220823

FZDE Discontinued

Effective date: 20220823